{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["28(5)"],"submitter":["Ram R"],"pubmed_abstract":["Patients with delayed B-cell reconstitution/B-cell aplasia after cellular therapy show decreased immunogenicity to the BNT162b2 mRNA COVID-19 vaccine. We prospectively evaluated both humoral and cellular immune response to a third vaccine dose in patients after allogeneic HCT (n = 10) or CD19-based chimeric antigen receptor T cells (CAR-T) therapy (n = 6) with low absolute B cell numbers and who failed to mount a humeral response after 2 vaccine doses. Humoral response was documented in 40% and 17% after allogeneic HCT and CAR-T therapy, respectively. None of the patients with complete B-cell aplasia developed anti-vaccine antibodies. Cellular response was documented in all patients after allogeneic HCT and in 83% of the patients after CAR-T. T-cell subclasses levels were not predictive fo"],"journal":["Transplantation and cellular therapy"],"pagination":["278.e1-278.e4"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8848544"],"repository":["biostudies-literature"],"pubmed_title":["Immunogenicity of a Third Dose of the BNT162b2 mRNA Covid-19 Vaccine in Patients with Impaired B Cell Reconstitution After Cellular Therapy-A Single Center Prospective Cohort Study."],"pmcid":["PMC8848544"],"pubmed_authors":["Freund T","Bar-On Y","Ram R","Halperin T","Beyar-Katz O","Ben-Ami R","Eilaty N","Gold R","Hagin D","Glait-Santar C","Kay S","Amit O"],"additional_accession":[]},"is_claimable":false,"name":"Immunogenicity of a Third Dose of the BNT162b2 mRNA Covid-19 Vaccine in Patients with Impaired B Cell Reconstitution After Cellular Therapy-A Single Center Prospective Cohort Study.","description":"Patients with delayed B-cell reconstitution/B-cell aplasia after cellular therapy show decreased immunogenicity to the BNT162b2 mRNA COVID-19 vaccine. We prospectively evaluated both humoral and cellular immune response to a third vaccine dose in patients after allogeneic HCT (n = 10) or CD19-based chimeric antigen receptor T cells (CAR-T) therapy (n = 6) with low absolute B cell numbers and who failed to mount a humeral response after 2 vaccine doses. Humoral response was documented in 40% and 17% after allogeneic HCT and CAR-T therapy, respectively. None of the patients with complete B-cell aplasia developed anti-vaccine antibodies. Cellular response was documented in all patients after allogeneic HCT and in 83% of the patients after CAR-T. T-cell subclasses levels were not predictive fo","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2026-05-03T03:16:27.02Z","creation":"2024-10-19T13:18:35.471Z"},"accession":"S-EPMC8848544","cross_references":{"pubmed":["35182795"],"doi":["10.1016/j.jtct.2022.02.012"]}}